|
EORTC aspect
|
MD (95 % C.I.)
|
p-value
|
|---|
|
C30 global quality of life
|
4.4 (−5.2, 14.1)
|
n.a.
|
|
C30 physical function
|
−3.1 (−10.9, 4.8)
|
n.a.
|
|
C30 role function
|
9.3 (−4.3, 23.0)
|
n.a.
|
|
C30 emotional function
|
−0.5 (−10.6, 9.6)
|
n.a.
|
|
C30 cognitive function
|
−5.9 (−13.5, 1.7)
|
n.a.
|
|
C30 social function
|
−2.3 (−14.5, 9.8)
|
n.a.
|
|
C30 fatigue
|
3.2 (−6.7, 13.1)
|
n.a.
|
|
C30 dyspnoea
|
−3.6 (−13.5, 6.3)
|
n.a.
|
|
OES18 dysphagia
|
−2.8 (−14.2, 8.6)
|
n.a.
|
- Mean score difference (MDs) were assessed with linear mixed-effect models and adjusted for time
- Charlson Comorbidity Index, neoadjuvant therapy, tumour stage, gender, histology, tumour site and complications. All these values did not show a significant time interaction term, i.e. the difference persisted over time. Any MD ≥ 10 was considered clinically significant and tested for statistical significance (n.a., not applicable, if MD < 10)
